Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

217 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Targeting FLT3 to treat leukemia.
Konig H, Levis M. Konig H, et al. Among authors: levis m. Expert Opin Ther Targets. 2015 Jan;19(1):37-54. doi: 10.1517/14728222.2014.960843. Epub 2014 Sep 18. Expert Opin Ther Targets. 2015. PMID: 25231999 Free PMC article. Review.
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.
Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD, Jones-Bolin S, Ruggeri B, Dionne C, Small D. Levis M, et al. Blood. 2002 Jun 1;99(11):3885-91. doi: 10.1182/blood.v99.11.3885. Blood. 2002. PMID: 12010785
Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay.
Murphy KM, Levis M, Hafez MJ, Geiger T, Cooper LC, Smith BD, Small D, Berg KD. Murphy KM, et al. Among authors: levis m. J Mol Diagn. 2003 May;5(2):96-102. doi: 10.1016/S1525-1578(10)60458-8. J Mol Diagn. 2003. PMID: 12707374 Free PMC article.
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.
Zheng R, Levis M, Piloto O, Brown P, Baldwin BR, Gorin NC, Beran M, Zhu Z, Ludwig D, Hicklin D, Witte L, Li Y, Small D. Zheng R, et al. Among authors: levis m. Blood. 2004 Jan 1;103(1):267-74. doi: 10.1182/blood-2003-06-1969. Epub 2003 Sep 11. Blood. 2004. PMID: 12969963
Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression.
Zheng R, Friedman AD, Levis M, Li L, Weir EG, Small D. Zheng R, et al. Among authors: levis m. Blood. 2004 Mar 1;103(5):1883-90. doi: 10.1182/blood-2003-06-1978. Epub 2003 Oct 30. Blood. 2004. PMID: 14592841
Novel FLT3 tyrosine kinase inhibitors.
Levis M, Small D. Levis M, et al. Expert Opin Investig Drugs. 2003 Dec;12(12):1951-62. doi: 10.1517/13543784.12.12.1951. Expert Opin Investig Drugs. 2003. PMID: 14640939 Review.
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, Murphy KM, Dauses T, Allebach J, Small D. Smith BD, et al. Among authors: levis m. Blood. 2004 May 15;103(10):3669-76. doi: 10.1182/blood-2003-11-3775. Epub 2004 Jan 15. Blood. 2004. PMID: 14726387 Clinical Trial.
Small molecule FLT3 tyrosine kinase inhibitors.
Levis M, Small D. Levis M, et al. Curr Pharm Des. 2004;10(11):1183-93. doi: 10.2174/1381612043452604. Curr Pharm Des. 2004. PMID: 15078134 Review.
In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects.
Levis M, Pham R, Smith BD, Small D. Levis M, et al. Blood. 2004 Aug 15;104(4):1145-50. doi: 10.1182/blood-2004-01-0388. Epub 2004 May 4. Blood. 2004. PMID: 15126317
Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition.
Brown P, Meshinchi S, Levis M, Alonzo TA, Gerbing R, Lange B, Arceci R, Small D. Brown P, et al. Among authors: levis m. Blood. 2004 Sep 15;104(6):1841-9. doi: 10.1182/blood-2004-03-1034. Epub 2004 May 27. Blood. 2004. PMID: 15166029
217 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback